Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that on January 31, 2018, the Company granted stock options and restricted stock units to eleven new employees of the company.

As quoted in the press release:

The stock options are to acquire, in the aggregate, 85,850 shares of the Company’s common stock at a per share exercise price of $15.25, the closing sales price on January 31, 2018, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service.

Click here to read the full press release.